182 research outputs found

    Glial TNFα in the spinal cord regulates neuropathic pain induced by HIV gp120 application in rats

    Get PDF
    <p>Abstract</p> <p>Background</p> <p>HIV-associated sensory neuropathy (HIV-SN) is one of the most common forms of peripheral neuropathy, affecting about 30% of people with acquired immune deficiency syndrome (AIDS). The symptoms of HIV-SN are dominated by neuropathic pain. Glia activation in the spinal cord has become an attractive target for attenuating chronic pain. This study will investigate the role of spinal TNFα released from glia in HIV-related neuropathic pain.</p> <p>Results</p> <p>Peripheral gp120 application into the rat sciatic nerve induced mechanical allodynia for more than 7 weeks, and upregulated the expression of spinal TNFα in the mRNA and the protein levels at 2 weeks after gp120 application. Spinal TNFα was colocalized with GFAP (a marker of astrocytes) and Iba1 (a marker of microglia) in immunostaining, suggesting that glia produce TNFα in the spinal cord in this model. Peripheral gp120 application also increased TNFα in the L4/5 DRG. Furthermore, intrathecal administration of TNFα siRNA or soluble TNF receptor reduced gp120 application-induced mechanical allodynia.</p> <p>Conclusions</p> <p>Our results indicate that TNFα in the spinal cord and the DRG are involved in neuropathic pain, following the peripheral HIV gp120 application, and that blockade of the glial product TNFα reverses neuropathic pain induced by HIV gp120 application.</p

    Controllable sliding transfer of wafer‐size graphene

    Get PDF
    The innovative design of sliding transfer based on a liquid substrate can succinctly transfer high‐quality, wafer‐size, and contamination‐free graphene within a few seconds. Moreover, it can be extended to transfer other 2D materials. The efficient sliding transfer approach can obtain high‐quality and large‐area graphene for fundamental research and industrial applications

    Identification of target genes of transcription factor activator protein 2 gamma in breast cancer cells

    Get PDF
    <p>Abstract</p> <p>Background</p> <p>Activator protein 2 gamma (AP-2γ) is a member of the transcription factor activator protein-2 (AP-2) family, which is developmentally regulated and plays a role in human neoplasia. AP-2γ has been found to be overexpressed in most breast cancers, and have a dual role to inhibit tumor initiation and promote tumor progression afterwards during mammary tumorigensis.</p> <p>Methods</p> <p>To identify the gene targets that mediate its effects, we performed chromatin immunoprecipitation (ChIP) to isolate AP-2γ binding sites on genomic DNA from human breast cancer cell line MDA-MB-453.</p> <p>Results</p> <p>20 novel DNA fragments proximal to potential AP-2γ targets were obtained. They are categorized into functional groups of carcinogenesis, metabolism and others. A combination of sequence analysis, reporter gene assays, quantitative real-time PCR, electrophoretic gel mobility shift assays and immunoblot analysis further confirmed the four AP-2γ target genes in carcinogenesis group: ErbB2, CDH2, HPSE and IGSF11. Our results were consistent with the previous reports that ErbB2 was the target gene of AP-2γ. Decreased expression and overexpression of AP-2γ in human breast cancer cells significantly altered the expression of these four genes, indicating that AP-2γ directly regulates them.</p> <p>Conclusion</p> <p>This suggested that AP-2γ can coordinate the expression of a network of genes, involving in carcinogenesis, especially in breast cancer. They could serve as therapeutic targets against breast cancers in the future.</p

    Current gene therapy using viral vectors for chronic pain

    Get PDF
    The complexity of chronic pain and the challenges of pharmacotherapy highlight the importance of development of new approaches to pain management. Gene therapy approaches may be complementary to pharmacotherapy for several advantages. Gene therapy strategies may target specific chronic pain mechanisms in a tissue-specific manner. The present collection of articles features distinct gene therapy approaches targeting specific mechanisms identified as important in the specific pain conditions. Dr. Fairbanks group describes commonly used gene therapeutics (herpes simplex viral vector (HSV) and adeno-associated viral vector (AAV)), and addresses biodistribution and potential neurotoxicity in pre-clinical models of vector delivery. Dr. Tao group addresses that downregulation of a voltage-gated potassium channel (Kv1.2) contributes to the maintenance of neuropathic pain. Alleviation of chronic pain through restoring Kv1.2 expression in sensory neurons is presented in this review. Drs Goins and Kinchington group describes a strategy to use the replication defective HSV vector to deliver two different gene products (enkephalin and TNF soluble receptor) for the treatment of post-herpetic neuralgia. Dr. Hao group addresses the observation that the pro-inflammatory cytokines are an important shared mechanism underlying both neuropathic pain and the development of opioid analgesic tolerance and withdrawal. The use of gene therapy strategies to enhance expression of the anti-pro-inflammatory cytokines is summarized. Development of multiple gene therapy strategies may have the benefit of targeting specific pathologies associated with distinct chronic pain conditions (by Guest Editors, Drs. C. Fairbanks and S. Hao)

    An analytical model for solid oxide fuel cells with bi-layer electrolyte

    No full text
    A theoretical model for a solid oxide fuel cell (SOFC) with a bi-layer electrolyte is developed and analytical solutions of various important relationships, such as I–V relationship, distribution of oxygen partial pressure in the bi-layer electrolyte, leakage current density etc. are obtained. Based on the assumptions of constant ionic conductivity and reversible electrodes, the model takes into considerations of transports of both ions and electrons in the electrolyte. The modeling results are compared with both experimental data and results from other models in the literature and very good agreements are obtained. ► An analytical model for a SOFC with a bi-layer electrolyte is developed. ► A set of analytical expressions for various relationships are obtained. ► Such relations include leakage current density, I–V relationship, open circuit voltage and oxygen partial pressure. ► The modeling results are compared with both experimental data and other models. ► Very good agreements are obtained

    A polarization model for solid oxide fuel cells with a Bi-layer electrolyte

    No full text
    A polarization model for a solid oxide fuel cell (SOFC) with a bi-layer electrolyte is developed and a set of explicit expressions for output current, maximum power and thickness ratio of bi-layer electrolyte are obtained. In the model, two dominating polarizations, activation polarization and ohmic polarization, are considered and the concentration polarization is neglected. The activation polarization at the electrodes is described by the Butler–Volmer equation. The ohmic polarization is represented by the charge transport equation, and this equation is solved with the assumption of constant ionic conductivity. To close the model equations, a supplemental relation is introduced by the energy conservation analysis. The modeling results compare well with the experimental data. The model is further used to study the effect of cathode exchange current density on the working characteristics of a solid oxide fuel cell with a bi-layer electrolyte. •A polarization model for a bi-layer electrolyte SOFC is developed.•Modeling results compared well with the experimental data.•OCV and output characteristics increase with cathode exchange current density.•Modeling results confirm optimal relative thickness from simplified models
    corecore